Company Overview and News

 
AstraZeneca announces investment of $90 million in India over next 5 years

2018-04-17 livemint
Bengaluru: Biopharmaceutical company AstraZeneca on Tuesday announced its decision to further invest $90 million in India over the next five years. The announcement was made following a meeting between the company’s executive vice-president for international region Leon Wang and Prime Minister Narendra Modi, who is now on a visit to Sweden, the company said.
Upvote Downvote

 
AstraZeneca Pharma India Limited - Press Release

2018-04-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
Upvote Downvote

 
AstraZeneca Pharma India Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
Upvote Downvote

 
What to watch: AstraZeneca launches diabetes drug

2018-02-15 thehindubusinessline
AstraZeneca Pharma India on Wednesday launched an anti-diabetic tablet ‘Xigduo XR’ used for the treatment of type 2 diabetes in adults. The drug is a product of AstraZeneca group and is approved in 61 countries, including the US, the EU and Japan, AstraZeneca said. It is a combination of metformin and dapagliflozin, an inhibitor of sodium-glucose cotransporter 2, it added. Xigduo XR is available in multiple dosage strengths.
Upvote Downvote

 
What to watch: AstraZeneca launches diabetes drug

2018-02-14 thehindubusinessline
AstraZeneca Pharma India on Wednesday launched an anti-diabetic tablet ‘Xigduo XR’ used for the treatment of type 2 diabetes in adults. The drug is a product of AstraZeneca group and is approved in 61 countries, including the US, the EU and Japan, AstraZeneca said. It is a combination of metformin and dapagliflozin, an inhibitor of sodium-glucose cotransporter 2, it added. Xigduo XR is available in multiple dosage strengths.
Upvote Downvote

 
AstraZeneca Pharma India Limited - Updates

2018-02-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
Upvote Downvote

 
AstraZeneca Pharma India Limited - Financial Result Updates

2018-02-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
Upvote Downvote

 
AstraZeneca Pharma India Limited - Updates

2017-12-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
Upvote Downvote

 
Torrent Power, Bharat Seats, AstraZeneca Pharma hits 52-wk high on strong Q2 nos

2017-11-07 moneycontrol
Shares Torrent Power, Bharat Seats and AstraZeneca Pharma touched 52-week high, gaining 5-20 percent intraday Tuesday on the back of strong Q2 (July-September) numbers.
Upvote Downvote

 
AstraZeneca Pharma India Q2 net zooms to Rs 27.38 crore

2017-11-06 moneycontrol
AstraZeneca Pharma India today reported a multi-fold jump in its net profit to Rs 27.38 crore for the quarter ended September 30, 2017 mainly on account of higher revenues and decrease in expenses.
Upvote Downvote

 
AstraZeneca gets regulator’s nod to sell diabetes drug

2017-10-17 thehindubusinessline
Drug firm AstraZeneca Pharma has received marketing authorisation from the Drug Controller General of India (DCGI) for Xigduo XR tablets used in treatment of adults with type 2 diabetes in India.
Upvote Downvote

 
AstraZeneca Pharma India gets DCGI nod to market diabetes drug

2017-10-17 business-standard
Drug firm AstraZeneca Pharma has received marketing authorisation from the Drug Controller General of India (DCGI) for Xigduo XR tablets used in treatment of adults with type 2 diabetes in India. The product is indicated as an adjunct therapy to diet and exercise to improve glycemic control in adults with type 2 diabetes, AstraZeneca Pharma India said in a statement.
Upvote Downvote

 
AstraZeneca Pharma India Limited - Updates

2017-10-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...